Dr. Eva Lonn MD, MSc, FRCP(C), FACC

Publications are listed in chronological order by descending date. Link takes user to pubMed for publication details.

• Effects of the once-weekly glucagon-like Peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.

  Source: Hypertension

• Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22,000 individuals.

  Source: Am J Clin Nutr

• Incremental value of left ventricular systolic and diastolic function to determine outcome in patients with acute ST-segment elevation myocardial infarction: the echocardiographic substudy of the OASIS-6 trial.

  Source: Echocardiography

• Darapladib for preventing ischemic events in stable coronary heart disease.

  Source: N Engl J Med

• Common carotid intima-media thickness measurements do not improve cardiovascular risk prediction in individuals with elevated blood pressure: the USE-IMT collaboration.

  Source: Hypertension

• Are the ACC/AHA guidelines on the treatment of blood cholesterol a game changer? A perspective from the Canadian Cardiovascular Society Dyslipidemia Panel.

  Source: Can J Cardiol

• Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET/TRANSCEND.

  Source: Clin Res Cardiol

• Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges.

  Source: Eur Heart J

• The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

  Source: Eur J Prev Cardiol

• Physical activity in patients with stable coronary heart disease: an international perspective.

  Source: Eur Heart J

• Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients.

  Source: Eur J Prev Cardiol

• Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia.

  Source: Atherosclerosis

• Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE).

  Source: Diabetes Care

• The relationship between anthropometric indexes of adiposity and vascular function in the FATE cohort.

  Source: Obesity (Silver Spring)

• Identification and management of patients at elevated cardiometabolic risk in canadian primary care: how well are we doing?

  Source: Can J Cardiol

• Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50,000 individuals.

  Source: Lancet

• 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult.

  Source: Can J Cardiol

• Multivitamins in prevention of cardiovascular disease.

  Source: JAMA

• Alcohol consumption and the risk of incident atrial fibrillation among people with cardiovascular disease.

  Source: CMAJ

• Pneumococcal endocarditis causing valve destruction in the absence of vegetations on transesophageal echocardiography: a series of 3 consecutive cases.

  Source: Can J Cardiol

• Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis.

  Source: JAMA

• The Relationship Between Anthropometric Indexes of Adiposity and Vascular Function in the FATE Cohort.

  Source: Obesity (Silver Spring)

• Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?

  Source: Eur Heart J

• Cardiovascular risk factors and subclinical atherosclerosis among Nunavik Inuit.

  Source: Atherosclerosis

• The fluid study protocol: a randomized controlled study on the effects of bioimpedance analysis and vitamin D on left ventricular mass in peritoneal dialysis patients.

  Source: Perit Dial Int

• Identification and management of cardiometabolic risk in Canada: a position paper by the cardiometabolic risk working group (executive summary).

  Source: Can J Cardiol

• Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group.

  Source: Can J Cardiol

• Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study.

  Source: Eur Heart J

• Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study.

  Source: Circulation

• Epicardial fat thickness and coronary artery disease correlate independently of obesity.

  Source: Int J Cardiol

• The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.

  Source: Circulation

• Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients.

  Source: Am J Cardiol

• Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: Meta-analysis of 8 randomized trials involving 37 485 individuals.

  Source: Arch Intern Med

• Lipoprotein-associated phospholipase A2: a new therapeutic target.

  Source: Can J Cardiol

• Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).

  Source: Am J Cardiol

• Polypill: the evidence and the promise.

  Source: Curr Opin Lipidol

• 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations.

  Source: Can J Cardiol

• Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.

  Source: Can J Cardiol

• Comparison of brachial and carotid artery ultrasound for assessing extent of subclinical atherosclerosis in HIV: a prospective cohort study.

  Source: AIDS Res Ther

• Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).

  Source: J Am Coll Cardiol

• Comparison of new measures of vascular function to flow mediated dilatation as a measure of cardiovascular risk factors.

  Source: Am J Cardiol

• The differential association between various anthropometric indices of obesity and subclinical atherosclerosis.

  Source: Atherosclerosis

• The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.

  Source: Clin Res Cardiol

• Lipid lowering for primary prevention.

  Source: Lancet

• The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.

  Source: J Cardiovasc Electrophysiol

• 5 flourouracil-induced apical ballooning syndrome: a case report.

  Source: Blood Coagul Fibrinolysis

• Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism.

  Source: Intern Emerg Med

• Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.

  Source: Stroke

• Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART).

  Source: Vasc Med

• Hemodynamic performance of stentless versus stented valves: a systematic review and meta-analysis.

  Source: J Card Surg

• Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction.

  Source: Am J Cardiol

• Resting heart rate: a modifiable prognostic indicator of cardiovascular risk and outcomes?

  Source: Can J Cardiol

• Homocysteine-lowering B vitamin therapy in cardiovascular prevention–wrong again?

  Source: JAMA

• BNP and NT-proBNP predict echocardiographic severity of diastolic dysfunction.

  Source: Eur J Heart Fail

• Cardiac function stratification based on echocardiographic or clinical markers of left ventricular filling pressures predicts death and hospitalization better than stratification by ventricular systolic function alone.

  Source: Echocardiography

• The effect of large unilamellar vesicles on vascular function in patients with coronary atherosclerosis.

  Source: Atherosclerosis

• Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascula

  Source: J Am Soc Echocardiogr

• Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis.

  Source: Am J Clin Nutr

• Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease–results of the renal Hope-2 study.

  Source: Nephrol Dial Transplant

• Randomized clinical trial of homocysteine level lowering therapy and fractures.

  Source: Arch Intern Med

• Homocysteine in the prevention of ischemic heart disease, stroke and venous thromboembolism: therapeutic target or just another distraction?

  Source: Curr Opin Hematol

• [Wrong focus in the debate on burnout].

  Source: Lakartidningen

• Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.

  Source: Am Heart J

• Prevalence and predictors of subclinical atherosclerosis among asymptomatic “low risk” individuals in a multiethnic population.

  Source: Atherosclerosis

• Modulation of arterial reactivity using amlodipine and atorvastatin measured by ultrasound examination (MARGAUX).

  Source: Atherosclerosis

• Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial.

  Source: Ann Intern Med

• Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.

  Source: Eur Heart J

• Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES.

  Source: J Am Coll Cardiol

• Giant left atrial myxoma and associated mitral valve pathology.

  Source: J Cardiothorac Vasc Anesth

• Impact of ramipril on the circadian periodicity of acute myocardial infarction.

  Source: Am J Cardiol

• The effect of iron status on vascular health.

  Source: Vasc Med

• Drug therapies in the secondary prevention of cardiovascular diseases: Successes, shortcomings and future directions.

  Source: Curr Vasc Pharmacol

• Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.

  Source: Circulation

• Apical ballooning syndrome or takotsubo cardiomyopathy: a systematic review.

  Source: Eur Heart J

• Homocysteine lowering with folic acid and B vitamins in vascular disease.

  Source: N Engl J Med

• Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?

  Source: Nat Clin Pract Cardiovasc Med

• Intensity of lipid lowering with statins and brachial artery vascular endothelium reactivity after acute coronary syndromes (from the BRAVER trial).

  Source: Am J Cardiol

• Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists’ Collaboration.

  Source: Eur Heart J

• The relationship between soluble CD40 ligand levels and Framingham coronary heart disease risk score in healthy volunteers.

  Source: Atherosclerosis

• Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.

  Source: Circulation

• Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke.

  Source: Am Heart J

• Surrogates of surrogates: the story of hypertension and 24 h blood pressure monitoring.

  Source: Can J Cardiol

• Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men.

  Source: J Am Coll Cardiol

• Perindopril in diabetes: perspective from the EUROPA substudy, PERSUADE.

  Source: Eur Heart J

• Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial.

  Source: JAMA

• Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.

  Source: Eur J Cardiovasc Prev Rehabil

• Reaching recommended lipid and blood pressure targets with amlodipine/atorvastatin combination in patients with coronary heart disease.

  Source: Am J Cardiol

• The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes.

  Source: Diabetes Care

• Cross-sectional evaluation of brachial artery flow-mediated vasodilation and C-reactive protein in healthy individuals.

  Source: Eur Heart J

• Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians.

  Source: Atherosclerosis

• The clinical relevance of pharmacological blood pressure lowering mechanisms.

  Source: Can J Cardiol

• C-reactive protein as a screening test for cardiovascular risk in a multiethnic population.

  Source: Arterioscler Thromb Vasc Biol

• Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.

  Source: J Am Coll Cardiol

• Prevalence of mitral valve prolapse in ethnic groups.

  Source: Can J Cardiol

• Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study.

  Source: Kidney Int

• Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.

  Source: Am J Cardiovasc Drugs

• Relationship of electrocardiographic left ventricular hypertrophy to mortality and cardiovascular morbidity in high-risk patients.

  Source: Eur J Cardiovasc Prev Rehabil

• Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity.

  Source: Can J Cardiol

• Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.

  Source: Am J Kidney Dis

• Gastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome.

  Source: Transfus Med Rev

• Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease.

  Source: Circulation

• Cardiovascular risk in patients with mild renal insufficiency.

  Source: Kidney Int Suppl

• Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.

  Source: Circulation

• Secondary prevention of ischaemic cardiac events.

  Source: Clin Evid

• Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.

  Source: J Am Soc Nephrol

• The fate of endothelial function testing: rationale and design of the Firefighters And Their Endothelium (FATE) study.

  Source: Can J Cardiol

• Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.

  Source: Circulation

• Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention.

  Source: Am Heart J

• The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study.

  Source: Diabetes Care

• Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy.

  Source: Diabetes Care

• Secondary prevention of ischaemic cardiac events.

  Source: Clin Evid

• Effect of long-term therapy with ramipril in high-risk women.

  Source: J Am Coll Cardiol

• Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in atherosclerosis.

  Source: Curr Atheroscler Rep

• Pathophysiologic and therapeutic importance of tissue ACE: a consensus report.

  Source: Cardiovasc Drugs Ther

• The T-786–>C mutation in endothelial nitric oxide synthase is associated with hypertension.

  Source: Hypertension

• Use of ramipril in preventing stroke: double blind randomised trial.

  Source: BMJ

• Dose response of ACE inhibitors: implications of the SECURE trial.

  Source: Curr Control Trials Cardiovasc Med